Posts by Sandra Ansanay-Alex
BioAlps Executive Committee: A Farewell and a Welcome
After more than 13 years of dedicated service on the BioAlps Executive Committee, Anne-Renée Leyvraz is stespping down from her role representing both UNIL and CHUV. Her retirement marks the end of a chapter that has left a lasting imprint on the organisation and on the broader Swiss Health Valley ecosystem. As Knowledge Transfer Manager…
Read MoreIsospec Analytics and MYSTONES Get a FIT Support
The Foundation for Innovation and Technology (FIT) is awarding a Tech Growth loan of CHF 400’000 to Isospec Analytics, an EPFL spin-off specialising in the identification of biological molecules for medical research. MYSTONES, an athlete tracking platform, gets a CHF 20’000 Digital Grant. Isospec Analytics: reading the molecules of the human body to improve treatment…
Read MoreCrìa Technologies Gets a CHF 100,000 FIF Seed Tech Support
Crìa Technologies is a Geneva-based and CSEM spin out startup addressing one of the most persistent logistical challenges in the life sciences: the safe, cost-efficient transport of fragile biological materials that require precise temperature control. The company has developed the world’s first portable device capable of operating across a temperature range from +8°C to -196°C.…
Read MoreGéraldine Blanchard-Rohner Gets a SNSF Support for Her Pertussis Vaccine Research
Géraldine Blanchard-Rohner, a privat-docent in the Department of Paediatrics, Gynaecology and Obstetrics and a member of the Centre for Inflammation Research (GCIR) at the University of Geneva Faculty of Medicine, as well as head of the Paediatric Immunology, Vaccinology and Rheumatology Unit at the HUG, will lead a major research project on new-generation pertussis vaccines.…
Read MoreSOPHiA GENETICS raises USD 57.5 million through a public offering
SOPHiA GENETICS, based in Canton of Vaud, announced the completion of its underwritten public offering, with total gross proceeds of $57.5 million, before deducting underwriting discounts, commissions and estimated offering expenses. The company sold 12,104,900 ordinary shares at $4.75 per share, according to a press release. The share is currently trading at $5.46, close to…
Read MoreDETECTRA and TUUS Solutions Receive a FIT Support
The Foundation for Innovation and Technology (FIT) is supporting two new life sciences startups in the Vaud region with Tech Seed loans. DETECTRA receives CHF 100’000 to develop its solution for remote monitoring of joint inflammation in patients with inflammatory arthritis. TUUS Solutions has received a CHF 100’000 loan to advance its dietary gel, designed…
Read MoreThree Leadership Appointments Shape Western Switzerland’s Health Landscape
June 2026 has brought a wave of significant leadership changes across Western Switzerland’s healthcare and life sciences sector, at Fondation La Source, Clinique Genolier, and at the European Association for Cancer Research (EACR). At the Clinique de Genolier, Aurélie Meynet has been appointed CEO, succeeding Stanley Hautdidier, who moves on to lead the newly created…
Read MoreMeditronFO: EPFL Launches the First Fully Transparent Medical AI Model
As artificial intelligence becomes increasingly prevalent in doctors’ surgeries and hospitals, one question arises: can we trust systems whose inner workings remain opaque? The LiGHT Laboratory (Laboratory for Intelligent Global Health Technologies) at EPFL , led by Professor Mary-Anne Hartley, has just released MeditronFO, a ‘Fully Open’ medical AI architecture — one that is entirely…
Read MoreOpen-I
Open-I is taking place on 26 November 2026 in Zurich Open-i brings together the key players in Switzerland’s innovation ecosystem: leading SMEs, start-ups, investors, corporates, academia, policymakers and the next generation of talent. The focus is on exchange, inspiration and tangible collaboration. Open-i shows how scientific insights can become new business models, market-ready solutions and…
Read MoreImmitra Bio receives CHF 150,000 from Venture Kick
The ETH spin-off and Geneva-based company Immitra Bio has received CHF 150,000 from Venture Kick to develop a new treatment approach for rare genetic diseases. The biotech startup aims to replace complex stem cell transplantation procedures with a single injection, making potentially curative therapies more accessible to patients worldwide. More than 7,000 rare genetic diseases…
Read More